
Exhibit 10.1   COLLABORATION AGREEMENT   THIS COLLABORATION AGREEMENT   ("Agreement") is  made  as of this 18t h  day  of  August 2014  (the "Effective  Date  "), by and between Capsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 ( "CAPSUGEL") and Cardax, Inc., and its Affiliates, with a corporate address at  2800  Woodlawn Dr., Suite 129, Honolulu, HI 96822 ("CARDAX"). CARDAX and CAPSUGEL are each a "Party" and together  constitute  the "Parties"   RECITALS   WHEREAS, CAPSUGEL is  experienced  in formulating,  developing  , manufacturing, testing and packaging of health and nutrition products; and   WHEREAS, CARDAX is  experienced  in  developing  products that are  based  on its astaxanthin technologies; and   WHEREAS, CAPSUGEL and CARDAX desire to  enter  into an arrangement under which the Product (as  defined  below) will be  formulated  and  developed  for the purpose of  identifying  a marketing partner(s) ("Marketer") for Marketer's onward sale of the Product in the Territory. NOW, THEREFORE, the Parties  hereto   agree  to the  following  :   SECTION 1   DEFINITIONS   The  following  terms for the purpose of this Agreement shall have the  following  respective meanings:   1.1 "Active Ingredient" shall mean the synthetic Astaxanthin and/or esters thereof that will be  formulated  in the Product as the active ingredient of the Product. 1.2 "Adjusted Net Sales" shall mean [***]. 1.3 "Administrative Cost" shall mean [***]. 1.4 "Affiliate" shall mean, with respect to either Party, all entities which, directly or indirectly, are  controlled  by, control or are under common control with such Party. For purposes of this Agreement, the word "control" shall mean the possession, directly or indirectly, of the power to  direct  or  cause  the direction of the management and policies of an entity,  including  through ownership of more than fifty percent (50%) of the voting shares or interest of an entity;  provided  , however, with respect to CAPSUGEL, the  term  "Affiliate" shall be  limited  to entities who directly or indirectly through one or more intermediaries are  controlled  by the parent of CAPSUGEL's direct parent entity and with respect to  CARDAX  the  term  "Affiliate" shall not  include  Cardax Pharmaceuticals, Inc. CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 1





    1.5 "Applicable Laws" shall mean all applicable laws, statutes, ordinances, codes, rules and regulations applicable to the formulation, development and/or manufacture, marketing, distribution sale, and disposal of the Product or any aspect thereof and the obligations of CAPSUGEL or CARDAX, as the context  requires  under this Agreement. 1.6 "Annual Period" shall mean the twelve (12)  month  period  beginning  on the first  day  in which the Launch  Date   occurs  and each twelve (12)  month  period  beginning  on the anniversary of such  day  thereafter. 1.7 "Commercially Reasonable Efforts" means a Party's reasonable efforts and diligence, consistent with professional business standards generally  practiced  in the health and nutrition industry,  applied  in accordance with the Party's commercially reasonable business, legal, medical and scientific judgment,  including  the efforts and resources the Party would  use  for a product  owned  by it or to which it has rights, which is of similar market potential at a similar stage in its product life,  taking  into account the competitiveness of the marketplace, the proprietary position of the compound, the Applicable Laws, the profitability of the applicable products, and other relevant factors  including  , without limitation, technical, legal, scientific or medical factors. 1.8 "Development Plan" shall have the meaning set forth in Section 2.1. 1.9 "Disclosing Party" shall have the meaning set forth in the Confidentiality Agreement. 1.10 "Formulation" means a specific combination of excipient(s) that can  formulate  the Active Ingredient, as well as compounds other than the Active Ingredient,  developed  as a result of the work  conducted  under the Development Plan. 1.11 "Force Majeure" shall have the meaning set forth in Section 10.5. 1.12 "Indemnified Party" shall have the meaning set forth in Section 8.3. 1.13 "Indemnifying Party" shall have the meaning set forth in Section 8.3. 1.14 "Intellectual Property Rights" means a composition of matter, formula, process, method of use, invention, improvement, business name, domain name or database right to the extent any of the foregoing is  protected  in a utility model, trademark, service mark, trade name or business name, copyright,  registered  design, design right, patent,  know  -how, trade secret, rights in or to confidential information all goodwill  related  thereto and any other intellectual property right of any nature whatsoever throughout the world (whether  registered  or unregistered and  including  all applications and rights to  apply  for the same). CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 2





    1.15 "Launch  Date  " shall mean the  date  [***]. 1.16 "Loss or Losses" shall mean any and all damages, fines, fees, settlements, payments, obligations, penalties, deficiencies, losses, costs and expenses,  including  , without limitation, environmental losses, interest, court costs, reasonable fees of attorneys, accountants and other experts and other reasonable expenses of litigation or other proceedings or of any claim, default or assessment. 1.17 "Manufacturing Facility" shall mean those areas of CAPSUGEL or CAPSUGEL's subcontractors manufacturing, packaging, laboratory and  warehousing  facilities  utilized  in the formulation, manufacture, packaging, storage, testing, shipping or receiving of the Product. 1.18 "Materials" mean all excipient(s) and inactive raw materials  used  in the formulation of the Product. For the avoidance of doubt, "Materials"  does  not  include  any Active Ingredient or work in process or finished goods inventory. 1.19 "Net Sales" means [***]. 1.20 "Product" shall mean Active Ingredient  Formulated  in CAPSUGEL's proprietary Lipid Multi-Particulate Technology,  including  any improvements or derivatives of such technology. 1.21 "Receiving Party" shall have the meaning set forth in the Confidentiality Agreement. 1.22 "Regulatory Approvals" means any and all approvals, licenses, registrations, or authorizations of the relevant Regulatory Authority, necessary for the development, manufacture, use, storage, import, transport, export or commercialization of the Product in a particular country or jurisdiction. 1.23 "Regulatory Authority (ies)" means any governmental regulatory authority within a Territory  involved  in  regulating  any aspect of the development, manufacture, testing, market approval, sale, distribution, packaging or use of the Product. 1.24 "Regulatory Filings" shall mean the registrations, permits, licenses, authorizations, presentations, notifications, filings and/or approvals (together with all applications therefore and all  related  documents  required  by the FDA and all other laws for the development, manufacture, use, importation, export, marketing, sale and distribution of the Product within the Territory. CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 3





    1.25 "Royalty Payment" shall have the meaning set forth in Section 5.1. 1.26 "Specifications" shall mean the Product description and attributes  agreed  upon between the Parties upon conclusion of the Development Plan and  appended  to this Agreement as Exhibit B that will be  attached  hereto and, when  attached  , will be a part hereof, prior to commercialization of the Product. 1.27 "Territory" shall mean worldwide. Section 2   Product Development, Manufacture and Commercialization   2.1 Governance Process Among the Parties . Both CARDAX and CAPSUGEL will  agree  upon a development plan, which shall be in writing and  attached  hereto as Exhibit A (the "Development Plan"), which shall  describe  various parameters  including  each Party's duties, obligations, time schedule and deliverables schedule. The activities  performed  under the Development Plan (the "Development Activities")  shall  be  administered  by a joint project team ("JPT"), which shall  review  / update  / amend  the Development Plan for the Product in the Territory and  coordinate  the Formulation, development, manufacturing and commercialization of the Product,  including   identifying  and  selecting  one or more Marketers as  contemplated  under Section 2.4. Each Party shall  appoint  a project manager to  oversee  that Party's performance of its obligations under this Agreement and shall  notify  the other Party of the name and full contact details of its  appointed  project manager. The  JPT shall  comply  with this Agreement for decisions specifically  assigned  to a Party pursuant to this Agreement. Meetings shall   take  place by telephone or in person and the JPT will  operate  by consensus. If consensus cannot be  reached  , the matter will be  submitted  to the Head of Dosage Form Solutions of CAPSUGEL and the President and CEO of CARDAX for resolution. If such matter is not  resolved  , then the Parties may  attempt  to  mediate  such issue under the JAMS mediation rules. No member or any Affiliate of any member of the JPT shall have any liability under this Agreement and shall be  exculpated  to the fullest extent not  prohibited  by law from any liability to any Party that such member is not an employee, officer, consultant or acting in any similar capacity. 2.2 CAPSUGEL Responsibilities. With respect to the Product, CAPSUGEL, [***] shall [***]  perform  the development work necessary to  formulate  , analytically  develop  and  take  all other developmental actions necessary or  required  to  develop  the Product and  manufacture  pre- clinical and clinical batches (collectively, the "CAPSUGEL Development Activities" ). For purposes of further clarification, CAPSUGEL Development Activities shall  include  , without limitation, each of the  following   performed  with all due diligence, care and skill and in accordance with all other Applicable Laws:

CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 4







  (a) Formulation Development. Formulation shall mean a specific combination of Materials that  formulate  the Active Ingredient, as well as compounds other than the Active Ingredient,  developed  as a result of the work  conducted  under the Development Plan. The development of the Formulation of the Product,  includes  without limitation, all stability tests and other studies as applicable,  providing  CARDAX reports of such stability tests,  using  Commercially Reasonable Efforts to  modify  the Formulation as necessary and  develop  processes capable of scale-up and commercialization in accordance with Applicable Laws. (b) Analytical Methods.  Developing  and validating analytical methods  including  but not  limited  to dissolution, assay, and stability as  agreed  upon by the Parties. (c) Manufacture of Study Batches. The manufacture [***] of batches of Product in amounts  specified  on or about the dates  determined  a s  reasonably necessary for  conducting  all  required  for CAPSUGEL/CARDAX  funded  studies. Any other batches  required  or reasonably  required  by the Marketer for  applying  for and all actions  related  to additional Regulatory Approvals and Regulatory Filings of the Product and any related communications, studies or support for the FDA or any other Regulatory Authority (ies), which may  include  human and animal studies, shall be  paid  for by the Marketer, unless the Parties  agree  otherwise. (d) Manufacturing Development. Development of  manufacturing  processes and systems in conformance with cGMP requirements of FDA to  manufacture  pilot batches, exhibit batches and commercial batches of Product. (e) Reporting. CAPSUGEL shall, throughout the performance of the Development Plan studies,  consult  with CARDAX on matters  including  technical, intellectual property and regulatory aspects and  keep  the other  apprised  of all developments. (f) Commercial Manufacturing. CAPSUGEL shall  manufacture  the Product for each Marketer unless otherwise  agreed  by the Parties and the applicable Marketer. 2.3 CARDAX Responsibilities. (a) CARDAX shall be responsible for [***] the Active Ingredient [***], subject to reasonable notice and delivery schedules and reasonable amounts  required  by CAPSUGEL for it to  perform  its obligations under this Agreement or as otherwise  agreed  by CARDAX. (b) [***]   CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 5





    2.4 Joint Responsibilities. [***]   The marketing of the Product shall be  carried  out by one or more mutually identified Marketer(s) by the JPT or otherwise in accordance with Section 2.1. CAPSUGEL and CARDAX will jointly  control  identification, decision rights, and terms for a Marketer as  determined  by the JPT or otherwise in accordance with Section 2.1. If a Marketer is not  identified  , or the terms are not  determined  , by the JPT or otherwise in accordance with Section 2.1, then the Marketer (and such terms) may be  designated  by either Party, subject to the reasonable approval of the other Party. Any additional costs/activities  required  from a Marketer will be subject to agreement of the JPT or otherwise as  provided  in Section 2.1,  including  but not  limited  to  pre   -   launch  out-of-pocket expenses and the funding of such costs and expenses. These costs will be  shared  [***]. 2.5 Ownership of Application. CARDAX shall  own  and  control  all information and rights in, to and under all Regulatory Approvals in the Territory ( including  all  associated  contents and correspondences) and applications therefore related to the Product and any other marketing authorizations within the Territory, unless otherwise mutually  agreed  upon by the Parties. Section 3   Intellectual Property Matters   3.1 Background IP. This Agreement shall not  change  ,  modify  or otherwise  affect  any rights to any confidential information, inventions, patents, patent applications or other Intellectual Property Rights  owned  or  developed  by either Party before the Effective  Date  or  developed  by a Party after the Effective  Date  other than under the terms of this Agreement ("Background IP"). This Agreement shall not  confer  on either Party any rights in and/or to any Background IP of the other party, except as otherwise  provided  in this Agreement. 3 .2  CAPSUGEL Property. CARDAX  acknowledges  that CAPSUGEL  possesses  certain inventions, processes,  know  -how, trade secrets, improvements, other intellectual properties and other assets,  including  but not  limited  to formulation recipes,  processing  details, laboratory analyses, analytical methods, procedures and techniques, computer technical expertise and software, which have been independently  developed  by CAPSUGEL,  including  but not  limited  to, the Background IP of CAPSUGEL (collectively "Capsugel Property"). CARDAX and CAPSUGEL  agree  that any Capsugel Property or improvements thereto which are  used  ,  improved  ,  modified  or  developed  by CAPSUGEL under or during the  term  of this Agreement are the product of CAPSGUEL's technical expertise  possessed  and  developed  by CAPSUGEL prior to the Effective  Date  and are the sole and exclusive property of CAPSUGEL. CERTAIN PORTIONS OF THIS EXHIBIT  HAVE   BEEN   OMITTED  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF  1934 . OMISSIONS  ARE   DESIGNATED  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   FILED  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 6





      3 . 3  CARDAX Property. CAPSUGEL  acknowledges  that CARDAX  possesses  certain inventions, processes,  know  -how, trade secrets, improvements, other intellectual properties and other assets, which have been independently  developed  by CARDAX,  including  but not  limited  to, the Background IP of CARDAX (collectively "CARDAX Property").
